Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology firm focused on developing targeted therapies for metastatic diseases, announced its second-quarter financial results for 2025, revealing a net loss of $5.7 million, or $1.99 per share, an improvement from the $7.4 million loss, or $16.75 per share, reported in the same quarter the previous year. The company's research and development expenses increased to $2.6 million from $2.2 million, while general and administrative expenses decreased to $3.1 million from $3.6 million. Calidi concluded the quarter with $5.3 million in cash and $0.1 million in restricted cash.
Among the quarter's highlights, Calidi shared new preclinical data on CLD-401 from its RedTail platform, demonstrating enhanced efficacy through the systemic delivery of an IL15 superagonist and immune-evasion via engineered CD55 expression. The company also successfully raised $4.6 million through a warrant inducement offering, bringing the total gross proceeds for 2025 to $15.7 million. A significant milestone was achieved with the FDA granting Fast Track Designation for CLD-201 in treating soft tissue sarcoma, alongside an open Investigational New Drug (IND) application for a Phase 1 trial.
Calidi Biotherapeutics is at the forefront of immuno-oncology, leveraging its proprietary RedTail platform to develop enveloped oncolytic viruses designed for systemic delivery to metastatic sites. This technology aims to protect the virus from immune clearance, enabling effective tumor lysis and the delivery of potent gene therapies to distant disease locations. The company's lead candidate from the RedTail platform is currently in IND-enabling studies, targeting non-small cell lung cancer, ovarian cancer, and other tumors with high unmet needs. Additionally, Calidi is advancing protected virotherapies for intratumoral and localized administration in clinical-stage developments.
For further details on Calidi Biotherapeutics' recent achievements and financial performance, visit https://ibn.fm/K3CfE. Investors and interested parties can also find the latest updates on CLDI in the company's newsroom at https://ibn.fm/CLDI.
